William Osler Health Service Brampton Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2019
NCT04001010
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

William Osler Health Service Brampton | William Osler Health System

Active Ingredients

Drugs in Phase 3 Trials (2)

cannabidiol (Epidiolex) (1 trial)

tetrahydrocannabinol (1 trial)

Drugs in Phase 2 Trials (1)

psilocybin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cachexia (Phase 3)

Neoplasms (Phase 3)

Wasting Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3